149 related articles for article (PubMed ID: 31710779)
61. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
[TBL] [Abstract][Full Text] [Related]
62. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
Cross NC; Reiter A
Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
[TBL] [Abstract][Full Text] [Related]
63. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
[TBL] [Abstract][Full Text] [Related]
64. Rare SUZ12 variants commonly cause an overgrowth phenotype.
Cyrus SS; Cohen ASA; Agbahovbe R; Avela K; Yeung KS; Chung BHY; Luk HM; Tkachenko N; Choufani S; Weksberg R; Lopez-Rangel E; ; Brown K; Saenz MS; Svihovec S; McCandless SE; Bird LM; Garcia AG; Gambello MJ; McWalter K; Schnur RE; An J; Jones SJM; Bhalla SK; Pinz H; Braddock SR; Gibson WT
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):532-547. PubMed ID: 31736240
[TBL] [Abstract][Full Text] [Related]
65. PDGFRB mutation causes autosomal-dominant Penttinen syndrome.
Aminkeng F
Clin Genet; 2015 Dec; 88(6):531. PubMed ID: 26507258
[TBL] [Abstract][Full Text] [Related]
66. Myeloid neoplasm with the abnormality of PDGFRB gene secondary interstitial pneumonia: A case report.
Liu G; Ouyang R; Chen P; Liu T; Zhou L; Shen C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 45(3):345-348. PubMed ID: 32386029
[TBL] [Abstract][Full Text] [Related]
67. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
68. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
Ishibashi T; Yaguchi A; Terada K; Ueno-Yokohata H; Tomita O; Iijima K; Kobayashi K; Okita H; Fujimura J; Ohki K; Shimizu T; Kiyokawa N
Exp Hematol; 2016 Mar; 44(3):177-88.e5. PubMed ID: 26703895
[TBL] [Abstract][Full Text] [Related]
69. Growth pattern of Rahman syndrome.
Takenouchi T; Uehara T; Kosaki K; Mizuno S
Am J Med Genet A; 2018 Mar; 176(3):712-714. PubMed ID: 29383847
[TBL] [Abstract][Full Text] [Related]
70. [Sporadic infantile myofibromatosis: Mutations with PDGFRB gain-of-function].
Dereure O
Ann Dermatol Venereol; 2017; 144(8-9):574-575. PubMed ID: 28756885
[No Abstract] [Full Text] [Related]
71. [Myofibroma/myofibromatosis: a clinicopathologic analysis of 9 cases].
Fu Y; Guan WY; Wu HY; Wu HY; Fan ZW; Ye Q; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):45-50. PubMed ID: 29325250
[No Abstract] [Full Text] [Related]
72. Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome.
Saultz JN; Kaffenberger BH; Taylor M; Heerema NA; Klisovic R
JAMA Dermatol; 2016 Dec; 152(12):1391-1393. PubMed ID: 27681117
[No Abstract] [Full Text] [Related]
73. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
[TBL] [Abstract][Full Text] [Related]
74. Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene.
Mudry P; Slaby O; Neradil J; Soukalova J; Melicharkova K; Rohleder O; Jezova M; Seehofnerova A; Michu E; Veselska R; Sterba J
BMC Cancer; 2017 Feb; 17(1):119. PubMed ID: 28183292
[TBL] [Abstract][Full Text] [Related]
75. Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a
Sramek M; Neradil J; Macigova P; Mudry P; Polaskova K; Slaby O; Noskova H; Sterba J; Veselska R
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200486
[TBL] [Abstract][Full Text] [Related]
76. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
Welsh SJ; Churchman ML; Togni M; Mullighan CG; Hagman J
Leukemia; 2018 Jan; 32(1):38-48. PubMed ID: 28555080
[TBL] [Abstract][Full Text] [Related]
77. Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel.
Chang F; Liu L; Fang E; Zhang G; Chen T; Cao K; Li Y; Li MM
J Mol Diagn; 2017 Jul; 19(4):613-624. PubMed ID: 28502725
[TBL] [Abstract][Full Text] [Related]
78. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM
Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685
[TBL] [Abstract][Full Text] [Related]
79. Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene.
Yamazaki M; Nakaseko C; Takeuchi M; Ozawa S; Ishizuka Y; Hatanaka Y; Oshima-Hasegawa N; Muto T; Tsukamoto S; Mitsukawa S; Ohwada C; Takeda Y; Mimura N; Iseki T; Fukazawa M; Sakaida E
Intern Med; 2019 Dec; 58(23):3449-3453. PubMed ID: 31327842
[TBL] [Abstract][Full Text] [Related]
80. ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC.
Berghoff AS; Birner P; Streubel B; Kenner L; Preusser M
APMIS; 2014 Sep; 122(9):867-72. PubMed ID: 24750504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
